CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 12, 2013, Pages 2132-2140

  Block, Geoffrey A ^a   Kilpatrick, Ryan D ^b   Lowe, Kimberly A ^b   Wang, Wenli ^c   Danese, Mark D ^c  

^a Denver Nephrologists PC   (United States)

^b AMGEN INC   (United States)

^c Outcomes Insights Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE; BIOLOGICAL MARKER; PTH PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CHRONIC KIDNEY DISEASE; DEATH; FEMALE; FOLLOW UP; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MINERAL AND BONE DISORDER; MORTALITY; NEWBORN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PRESCHOOL CHILD; RISK; SCHOOL CHILD; SENSITIVITY ANALYSIS; BLOOD; BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; CALCIUM; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHENOTYPE; PHOSPHATES; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889801983     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04260413     Document Type: Article

References (18)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
3. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
5. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ: Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 3: 1423-1429, 2008
6. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individualswith chronic kidney disease: A systematic reviewand meta-analysis. JAMA 305: 1119-1127, 2011
7. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
9. Schisterman EF, Cole SR, Platt RW: Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20: 488-495, 2009
10. Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, Salusky I, Kalantar-Zadeh K: Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant 28: 1516-1525, 2013
11. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
12. Greenland S, Pearl J, Robins JM: Causal diagrams for epidemiologic research. Epidemiology 10: 37-48, 1999
13. US Renal Data System: USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
14. Glynn RJ, Gagne JJ, Schneeweiss S: Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf 21[Suppl 2]: 138-147, 2012
15. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ: An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 77: 141-151, 2010
16. St. Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA: Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4: 354-360, 2009
17. US Renal Data System: USRDS 2012 Annual Data Report Appendix: Analytical Methods, ESRD, 2012. Available at: http://www.usrds.org/2012/pdf/v2_z_appendix_12.pdf. Accessed December 5, 2012.
18. Centers for Medicare & Medicaid Services (CMS); HHS: Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. Final rule. Fed Regist 77: 67450-67531, 2012